AP NEWS

Global Von Willebrand Disease Treatment Market Report 2019-2023 - ResearchAndMarkets.com

December 14, 2018

DUBLIN--(BUSINESS WIRE)--Dec 14, 2018--The “Global Von Willebrand Disease Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.

The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients’ perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually.

Market Overview

Rising number of assistance programs for patients

The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.

Cost intensive treatment

High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.

Competitive Landscape

The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL, the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

01: Executive Summary

02: Scope Of The Report

03: Market Landscape

04: Market Sizing

05: Five Forces Analysis

06: Market Segmentation By Product

07: Customer Landscape

08: Geographic Landscape

09: Decision Framework

10: Drivers And Challenges

11: Market Trends

12: Vendor Landscape

13: Vendor Analysis

Baxter CSL Grifols Octapharma Shire

For more information about this report visit https://www.researchandmarkets.com/research/7zcbf8/global_von?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181214005218/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematology ,Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PHYSICAL THERAPY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/14/2018 08:09 AM/DISC: 12/14/2018 08:09 AM

http://www.businesswire.com/news/home/20181214005218/en

AP RADIO
Update hourly